Cogent Biosciences (COGT) Stock Forecast, Price Target & Predictions
COGT Stock Forecast
Cogent Biosciences stock forecast is as follows: an average price target of $18.50 (represents a 74.04% upside from COGT’s last price of $10.63) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
COGT Price Target
The average price target for Cogent Biosciences (COGT) is $18.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $13.00. This represents a potential 74.04% upside from COGT's last price of $10.63.
COGT Analyst Ratings
According to 6 Wall Street analysts, Cogent Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for COGT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cogent Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 03, 2024 | David Lebowitz | Citigroup | $13.00 | $10.95 | 18.72% | 22.30% |
| Sep 03, 2024 | Robert Burns | H.C. Wainwright | $17.00 | $11.37 | 49.52% | 59.92% |
| Mar 30, 2024 | Kelly Shi | Jefferies | $20.00 | $6.72 | 197.62% | 88.15% |
| Dec 14, 2022 | - | Needham | $24.00 | $12.32 | 94.81% | 125.78% |
| Jun 17, 2022 | Chris Raymond | Raymond James | $22.00 | $9.19 | 139.39% | 106.96% |
| Jun 10, 2022 | Christopher Liu | Leerink Partners | $15.00 | $10.74 | 39.66% | 41.11% |
The latest Cogent Biosciences stock forecast, released on Sep 03, 2024 by David Lebowitz from Citigroup, set a price target of $13.00, which represents a 18.72% increase from the stock price at the time of the forecast ($10.95), and a 22.30% increase from COGT last price ($10.63).
Cogent Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 3 |
| Avg Price Target | $15.00 | $15.00 | $16.67 |
| Last Closing Price | $10.63 | $10.63 | $10.63 |
| Upside/Downside | 41.11% | 41.11% | 56.82% |
In the current month, the average price target of Cogent Biosciences stock is $15.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 41.11% increase as opposed to Cogent Biosciences's last price of $10.63. This month's average price target is down 0.00% compared to last quarter, and down -10.02% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 14, 2022 | Needham | - | Buy | Initialise |
| Dec 13, 2022 | Guggenheim | Buy | Buy | Hold |
| Jun 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 10, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Cogent Biosciences's last stock rating was published by Citigroup on Sep 03, 2024. The company gave COGT a "Buy" rating, the same as its previous rate.
Cogent Biosciences Financial Forecast
Cogent Biosciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $312.00K | $528.00K | $7.03M | $15.29M | $1.02M | $3.14M | $3.05M | $2.04M | $1.67M | $2.22M |
| Avg Forecast | $1.68M | $1.09M | $588.63K | $179.93K | - | - | - | - | - | $50.00K | $1.98M | $452.57K | $2.00M | $3.74M | $3.52M | $3.25M | $3.11M | $3.47M | $1.81M | $2.06M |
| High Forecast | $1.68M | $1.09M | $588.63K | $179.93K | - | - | - | - | - | $50.00K | $2.38M | $543.09K | $2.00M | $3.74M | $3.52M | $3.25M | $3.11M | $4.16M | $2.18M | $2.47M |
| Low Forecast | $1.68M | $1.09M | $588.63K | $179.93K | - | - | - | - | - | $50.00K | $1.58M | $362.06K | $2.00M | $3.74M | $3.52M | $3.25M | $3.11M | $2.77M | $1.45M | $1.65M |
| # Analysts | - | - | - | - | - | - | - | 7 | 8 | 5 | 11 | 13 | 7 | 6 | 5 | 5 | 5 | 13 | 7 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.16% | 1.17% | 3.52% | 4.08% | 0.29% | 0.97% | 0.98% | 0.59% | 0.92% | 1.08% |
Cogent Biosciences's average Quarter revenue forecast for Dec 23 based on 8 analysts is -, with a low forecast of -, and a high forecast of -. COGT's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of - (Dec 20).
Cogent Biosciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 7 | 8 | 5 | 11 | 13 | 7 | 6 | 5 | 5 | 5 | 13 | 7 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | $-57.43M | $-11.32M | $-49.86M | $-7.11M | $-5.80M | $2.61M | $-11.61M | $-10.19M | $-11.36M | $-9.84M | $-8.70M | $-6.42M |
| Avg Forecast | $335.82K | $217.17K | $117.73K | $35.99K | - | - | - | - | - | $10.00K | $-316.53M | $-6.09M | $-7.83M | $748.80K | $-9.28M | $-11.71M | $-9.40M | $-16.70M | $-9.47M | $-5.92M |
| High Forecast | $335.82K | $217.17K | $117.73K | $35.99K | - | - | - | - | - | $10.00K | $-253.22M | $-4.87M | $-6.26M | $748.80K | $-7.43M | $-9.37M | $-7.52M | $-13.36M | $-7.57M | $-4.74M |
| Low Forecast | $335.82K | $217.17K | $117.73K | $35.99K | - | - | - | - | - | $10.00K | $-379.83M | $-7.31M | $-9.39M | $748.80K | $-11.14M | $-14.06M | $-11.28M | $-20.04M | $-11.36M | $-7.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | -1132.21% | 0.16% | 1.17% | 0.74% | 3.49% | 1.25% | 0.87% | 1.21% | 0.59% | 0.92% | 1.08% |
7 analysts predict COGT's average Quarter EBITDA for Mar 20 to be $-7.83M, with a high of $-6.26M and a low of $-9.39M. This is -399.74% lower than Cogent Biosciences's previous annual EBITDA (Dec 19) of $2.61M.
Cogent Biosciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 7 | 8 | 5 | 11 | 13 | 7 | 6 | 5 | 5 | 5 | 13 | 7 | 14 |
| Net Income | - | - | - | - | - | - | - | - | $-54.37M | $-11.34M | $-49.98M | $-7.39M | $-6.09M | $2.30M | $-11.92M | $-10.52M | $-11.69M | $-10.17M | $-9.02M | $-6.74M |
| Avg Forecast | $-55.06M | $-54.35M | $-53.40M | $-53.29M | $-56.47M | $-56.19M | $-55.28M | $-48.78M | $-48.07M | $-44.23M | $-317.30M | $-6.34M | $-8.22M | $-93.67M | $-9.54M | $-12.09M | $-9.67M | $-17.26M | $-9.82M | $-6.21M |
| High Forecast | $-55.06M | $-54.35M | $-53.40M | $-53.29M | $-56.47M | $-44.95M | $-55.28M | $-48.78M | $-32.94M | $-44.23M | $-253.84M | $-5.07M | $-6.58M | $-93.67M | $-7.63M | $-9.67M | $-7.74M | $-13.81M | $-7.86M | $-4.97M |
| Low Forecast | $-55.06M | $-54.35M | $-53.40M | $-53.29M | $-56.47M | $-68.45M | $-55.28M | $-48.78M | $-58.75M | $-44.23M | $-380.76M | $-7.60M | $-9.87M | $-93.67M | $-11.45M | $-14.51M | $-11.60M | $-20.71M | $-11.78M | $-7.46M |
| Surprise % | - | - | - | - | - | - | - | - | 1.13% | 0.26% | 0.16% | 1.17% | 0.74% | -0.02% | 1.25% | 0.87% | 1.21% | 0.59% | 0.92% | 1.08% |
Cogent Biosciences's average Quarter net income forecast for Mar 20 is $-8.22M, with a range of $-9.87M to $-6.58M. COGT's average Quarter net income forecast represents a -458.05% decrease compared to the company's last Quarter net income of $2.30M (Dec 19).
Cogent Biosciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 7 | 8 | 5 | 11 | 13 | 7 | 6 | 5 | 5 | 5 | 13 | 7 | 14 |
| SG&A | - | - | - | - | - | - | - | - | $9.51M | $5.35M | $52.51M | $2.80M | $3.67M | $2.69M | $2.72M | $3.06M | $2.49M | $2.37M | $1.98M | $1.06M |
| Avg Forecast | $1.91M | $1.24M | $671.15K | $205.16K | - | - | - | - | - | $57.01K | $2.26M | $516.01K | $2.28M | $4.27M | $2.18M | $3.70M | $2.06M | $3.95M | $2.07M | $981.60K |
| High Forecast | $1.91M | $1.24M | $671.15K | $205.16K | - | - | - | - | - | $57.01K | $2.71M | $619.22K | $2.28M | $4.27M | $2.61M | $3.70M | $2.47M | $4.74M | $2.48M | $1.18M |
| Low Forecast | $1.91M | $1.24M | $671.15K | $205.16K | - | - | - | - | - | $57.01K | $1.81M | $412.81K | $2.28M | $4.27M | $1.74M | $3.70M | $1.65M | $3.16M | $1.65M | $785.28K |
| Surprise % | - | - | - | - | - | - | - | - | - | 93.81% | 23.25% | 5.43% | 1.61% | 0.63% | 1.25% | 0.83% | 1.21% | 0.60% | 0.96% | 1.08% |
Cogent Biosciences's average Quarter SG&A projection for Mar 24 is -, based on 7 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to COGT last annual SG&A of $9.51M (Dec 23).
Cogent Biosciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 7 | 8 | 5 | 11 | 13 | 7 | 6 | 5 | 5 | 5 | 13 | 7 | 14 |
| EPS | - | - | - | - | - | - | - | - | $-0.63 | $-0.59 | $-5.07 | $-0.96 | $-0.80 | $0.28 | $-1.56 | $-1.36 | $-1.56 | $-1.36 | $-1.24 | $-2.64 |
| Avg Forecast | $-0.55 | $-0.55 | $-0.54 | $-0.54 | $-0.57 | $-0.57 | $-0.56 | $-0.51 | $-0.55 | $-0.51 | $-0.56 | $-0.84 | $-1.20 | $-1.08 | $-1.24 | $-1.54 | $-1.28 | $-0.59 | $-0.37 | $-0.33 |
| High Forecast | $-0.55 | $-0.55 | $-0.54 | $-0.54 | $-0.57 | $-0.45 | $-0.56 | $-0.51 | $-0.38 | $-0.51 | $-0.56 | $-0.84 | $-1.20 | $-1.08 | $-1.24 | $-1.54 | $-1.28 | $-0.48 | $-0.30 | $-0.27 |
| Low Forecast | $-0.55 | $-0.55 | $-0.54 | $-0.54 | $-0.57 | $-0.69 | $-0.56 | $-0.51 | $-0.68 | $-0.51 | $-0.56 | $-0.84 | $-1.20 | $-1.08 | $-1.24 | $-1.54 | $-1.28 | $-0.71 | $-0.44 | $-0.40 |
| Surprise % | - | - | - | - | - | - | - | - | 1.14% | 1.16% | 9.05% | 1.14% | 0.67% | -0.26% | 1.26% | 0.88% | 1.22% | 2.31% | 3.35% | 8.00% |
According to 7 Wall Street analysts, Cogent Biosciences's projected average Quarter EPS for Mar 20 is $-1.20, with a low estimate of $-1.20 and a high estimate of $-1.20. This represents a -528.57% decrease compared to COGT previous annual EPS of $0.28 (Dec 19).
Cogent Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $3.24 | $21.86 | 574.69% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| KALV | KalVista Pharmaceuticals | $11.14 | $26.00 | 133.39% | Buy |
| OLMA | Olema Pharmaceuticals | $12.70 | $27.00 | 112.60% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| COGT | Cogent Biosciences | $10.63 | $18.50 | 74.04% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $25.26 | $37.00 | 46.48% | Buy |
| MRSN | Mersana Therapeutics | $2.11 | $3.00 | 42.18% | Buy |
| KURA | Kura Oncology | $20.88 | $28.67 | 37.31% | Buy |
| IDYA | IDEAYA Biosciences | $37.46 | $46.13 | 23.14% | Buy |
| VRNA | Verona Pharma | $29.78 | $33.00 | 10.81% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
COGT Forecast FAQ
Is Cogent Biosciences a good buy?
Yes, according to 6 Wall Street analysts, Cogent Biosciences (COGT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of COGT's total ratings.
What is COGT's price target?
Cogent Biosciences (COGT) average price target is $18.5 with a range of $13 to $24, implying a 74.04% from its last price of $10.63. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cogent Biosciences stock go up soon?
According to Wall Street analysts' prediction for COGT stock, the company can go up by 74.04% (from the last price of $10.63 to the average price target of $18.5), up by 125.78% based on the highest stock price target, and up by 22.30% based on the lowest stock price target.
Can Cogent Biosciences stock reach $20?
COGT's highest twelve months analyst stock price target of $24 supports the claim that Cogent Biosciences can reach $20 in the near future.
What is Cogent Biosciences's current price target trend?
2 Wall Street analysts forecast a $15 price target for Cogent Biosciences (COGT) this month, up 41.11% from its last price of $10.63. Compared to the last 3 and 12 months, the average price target increased by 41.11% and increased by 56.82%, respectively.
What are Cogent Biosciences's analysts' financial forecasts?
Cogent Biosciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-217M (high $-205M, low $-229M), average SG&A $0 (high $0, low $0), and average EPS is $-2.207 (high $-2.094, low $-2.33). COGT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.53M (high $3.53M, low $3.53M), average EBITDA is $706.7K (high $706.7K, low $706.7K), average net income is $-216M (high $-216M, low $-216M), average SG&A $4.03M (high $4.03M, low $4.03M), and average EPS is $-2.177 (high $-2.177, low $-2.177).
Did the COGT's actual financial results beat the analysts' financial forecasts?
Based on Cogent Biosciences's last annual report (Dec 2020), the company's revenue was $7.87M, beating the average analysts forecast of $4.48M by 75.57%. Apple's EBITDA was $-89.692M, missing the average prediction of $-330M by -72.86%. The company's net income was $-59.204M, missing the average estimation of $-376M by -84.26%. Apple's SG&A was $17.42M, beating the average forecast of $5.11M by 240.83%. Lastly, the company's EPS was $-5.34, beating the average prediction of $-3.11 by 71.70%. In terms of the last quarterly report (Dec 2020), Cogent Biosciences's revenue was $0.000008, missing the average analysts' forecast of $50K by -100.00%. The company's EBITDA was $-11.321M, missing the average prediction of $10K by -113321.32%. Cogent Biosciences's net income was $-11.338M, missing the average estimation of $-44.232M by -74.37%. The company's SG&A was $5.35M, beating the average forecast of $57.01K by 9280.97%. Lastly, the company's EPS was $-0.594, beating the average prediction of $-0.51 by 16.47%